Associated Papers
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S8
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_3.xlsx › EGFR_mutations
The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations.
Ma F et al.
Nature Communications, 2022
36163440 (PubMed )
Supplement: 41467_2022_33351_MOESM6_ESM.xlsx › PTC_US
Complete Screening of Exons 2, 3, and 4 of KRAS and NRAS Genes Reveals a Higher Number of Clinically Relevant Mutations than Food and Drug Administration Quantitative Polymerase Chain Reaction-Based Commercial Kits.
Sánchez-Ibarra HE et al.
Revista De Investigacion Clinica; Organo Del Hospital De Enfermedades De La Nutricion, 2020
Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?
Zilberg C et al.
Journal of Clinical Pathology, 2020
Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.
Alvarez-Cubero MJ et al.
Molecular Diagnosis & Therapy, 2017
A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
Kawazoe A et al.
Bmc Cancer, 2015
25886136 (PubMed )
Supplement: 12885_2015_1276_MOESM1_ESM.xlsx › Addtional_file_1
SNaPshot and StripAssay as valuable alternatives to direct sequencing for KRAS mutation detection in colon cancer routine diagnostics.
Fariña Sarasqueta A et al.
The Journal of Molecular Diagnostics : Jmd, 2011
High sensitive mutation analysis on KRAS gene using LNA/DNA chimeras as PCR amplification blockers of wild-type alleles.
Huang Q et al.
Molecular and Cellular Probes, 2010
Select a paper to view details